Baylor College of Medicine opens cancer bioinformatics postdoctoral role focused on multi-omics and spatial data

Baylor College of Medicine is recruiting a Postdoctoral Associate for a cancer research program built around bioinformatics, biostatistics, and multi-omics analysis. The appointment is centered in Dr. Putluri’s laboratory in Houston and is designed for a researcher who can move comfortably between computational pipelines, translational specimens, and experimental cancer biology. The position carries a salary of $63,480 and is listed as a Monday through Friday role, 8 a.m. to 5 p.m., with a closing date of 13 Jan 2027.

The scientific scope is unusually broad for a single postdoctoral post. The successful candidate is expected to work across bulk RNA-seq, single-cell RNA-seq, proteomics, metabolomics, ATAC-seq, ChIP-seq, spatial transcriptomics, spatial proteomics, spatial metabolomics, and imaging mass cytometry or CyTOF. In practical terms, this means the role sits at the intersection of tumor genomics, chromatin biology, immune profiling, and computational systems biology, with an emphasis on finding the molecular circuitry that drives progression and therapy resistance.

A major part of the work will involve multi-omics integration. Cancer rarely announces itself through one molecular layer alone. Expression shifts, epigenetic remodeling, proteomic rewiring, and metabolic adaptation often occur together, and the job description reflects that complexity by requiring statistical modeling, pathway and network analysis, biomarker discovery, and reproducible workflow development. The laboratory is clearly looking for someone who can connect those layers into interpretable biological mechanisms rather than treating each dataset as an isolated technical exercise.

The emphasis on metabolic reprogramming is especially notable. Cancer cells alter nutrient use, redox balance, and signaling pathways to survive hostile microenvironments and evade treatment pressure. Pairing metabolomics with transcriptomics and proteomics gives the lab a way to trace those changes from phenotype back to regulatory logic. In a translational setting, that kind of analysis can expose vulnerabilities that may not be visible in conventional histology or single-platform sequencing studies.

A computational postdoc with a translational cancer biology remit

The position is not limited to data analysis alone. The selected fellow will also be expected to participate in in vitro cancer biology, including 2D culture, 3D organoids, spheroids, and patient-derived models. CRISPR/Cas9-mediated knockout, siRNA or shRNA knockdown, and validation of engineered cell lines are also part of the remit, along with molecular and biochemical assays and functional phenotyping. In other words, the role is designed for a scientist who can move from code to bench and back again without losing mechanistic focus.

Mouse work is also embedded in the postdoctoral duties. The appointment includes studies in immune-competent strains and NSG mice, tumor implantation, drug treatment, and immune profiling. Luciferase labeling and bioluminescence imaging are listed as tools for tracking tumor growth and metastasis in vivo. Those methods make the position particularly relevant to questions of tumor dissemination, treatment response, and immune-tumor interaction, where spatial and temporal readouts can change the interpretation of a therapeutic effect.

The computational side is equally demanding. The postdoc will be expected to develop and maintain reproducible pipelines, work in Linux or Unix environments, use command-line tools, and handle large-scale datasets with HPC and cloud resources when appropriate. R and Python are central requirements, not optional extras. So are version control, documentation, quality control, and the ability to troubleshoot workflows independently. For a lab working at this scale, reproducibility is not a stylistic preference; it is the difference between a usable analytical framework and an archive of disconnected scripts.

High-dimensional data types bring a specific analytic burden. Single-cell RNA-seq demands clustering, cell-state analysis, trajectory inference, and cell-cell communication modeling. Spatial transcriptomics adds another layer, because location within tissue can determine whether a cell is behaving like a bystander, a responder, or a driver of local invasion. Imaging mass cytometry and CyTOF expand the question again by allowing high-dimensional phenotyping across tissue sections, where cellular composition and spatial organization can shape immune exclusion or immune engagement.

The post is built for scientists who can bridge statistics and mechanism

Several responsibilities point to the need for strong statistical judgment. Multivariable regression, survival analysis, longitudinal analysis, correlation analysis, clustering, dimensionality reduction, and predictive modeling are all explicitly named. The laboratory is therefore signaling a preference for candidates who understand not just how to run an analysis, but how to choose the right design, avoid overfitting, and interpret findings in a biologically defensible way.

The qualifications reflect that expectation. An MD or Ph.D. in a basic science, health science, or related field is required, with no experience required at the minimum level. Preferred backgrounds include bioinformatics, computational biology, biostatistics, statistics, biomedical informatics, data science, cancer biology, genomics, and systems biology. Prior work with RNA-seq, single-cell datasets, spatial transcriptomics, proteomics, metabolomics, ATAC-seq, ChIP-seq, or CyTOF would fit naturally into the role.

A separate preference for experience with 3D culture systems and mouse models suggests a lab that wants more than a purely computational profile. The most attractive candidate will likely be one who can interpret molecular findings in the context of actual tumor behavior, then validate those signals in a model system. That combination is particularly relevant in cancer research, where statistical significance alone does not guarantee biological relevance, and where translational claims depend on linkage to experimental confirmation.

The post also includes manuscript preparation, figure generation, grant support, and presentation responsibilities. Those tasks matter because they place the fellow inside the full scientific production pipeline, from raw data to publication-ready output. A strong publication record and excellent communication skills are listed among the preferred qualifications, which fits a role expected to contribute to both discovery and dissemination.

For Baylor College of Medicine, the opening signals continued investment in a research model that treats cancer as a systems problem. The lab’s focus on tumor cell signaling, metabolic vulnerabilities, therapeutic resistance, and tumor-immune interactions aligns tightly with the data types named in the posting. The position offers access to patient-derived models, 3D organoids and spheroids, advanced molecular assays, and clinically annotated human specimens. In a field where multi-omics studies can stall without the right analytic and experimental infrastructure, this postdoctoral role is built to keep those components connected from the first computational pass to the final biological readout.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Nature Reviews Clinical Oncology.